SNYSanofi

Nasdaq sanofi.com


$ 50.12 $ 1.14 (2.33 %)    

Tuesday, 25-Jun-2024 15:59:59 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 50.11
$ 48.56
$ 0.00 x 0
$ 50.42 x 239
$ 48.48 - $ 50.26
$ 40.90 - $ 53.45
3,156,276
na
62.96B
$ 0.58
$ 10.54
TBD
na
na ($ 0.08)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sanofi-seeks-bids-for-20b-consumer-arm-by-mid-july-advent-pai-among-top-suitors-blackstone-cdr-cvc-and-tpg-also-interested

- Bloomberg Citing Sources

 sanofi-to-present-altuviiios-long-term-efficacy-and-fitusirans-prophylaxis-potential-at-isth

ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the...

 industry-groups-back-gsks-effort-to-halt-70000-lawsuits-associated-with-heartburn-drug-zantac-caused-cancer

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threat...

Core News & Articles

SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a jo...

Core News & Articles

-Reuters

 sanofi-highlights-data-from-blood-cancer-drug-sarclisa-in-new-diagnosed-multiple-myeloma-patients

Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, t...

 zantac-heart-burn-continues-for-gsk-as-us-court-ruling-allows-thousands-of-zantac-lawsuits-to-move-forward

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (rani...

 dhl-supply-chain-expands-pharma-logistics-operations-in-france---dhl-group

https://group.dhl.com/en/media-relations/press-releases/2024/dhl-supply-chain-expands-pharma-logistics-operations-in-france.html

 fda-extends-review-deadline-for-regeneronsanofis-dupixent-for-smokers-lungs-disease

The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 202...

Core News & Articles

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COP...

Core News & Articles

The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the sup...

 veecon-2024-speakers-announced-x-ceo-linda-yaccarino-content-creator-khaby-lame-gary-vee-among-special-guests-to-appear-at-festival-that-combines-business-pop-culture-web3

For the third straight year, serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) will host an annual conf...

 reported-monday-sanofis-sarclisa-accepted-for-fda-priority-review-for-treating-transplant-ineligible-newly-diagnosed-multiple-myeloma

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Pr...

 zantac-verdict-jury-finds-no-link-to-colon-cancer-in-initial-trial-gsk-and-boehringer-prevail-in-first-zantac-cancer-lawsuit

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies d...

 first-advanced-oral-treatment-for-asthma---sanofis-investigational-drug-shows-potential

Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma ...

 hawaii-court-rules-against-bristol-myers-sanofi-in-blood-clot-drug-case-increases-liability-to-916m

A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the hea...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION